Newsfeeds - Spark Newswire

1 minute read

Puma Biotechnology Q2 EPS $(0.13) Beats $(0.34) Estimate, Sales $53.40M Beat $51.60M Estimate

Today, 2:25 PM

Puma Biotechnology (NASDAQ:PBYI) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.34) by 61.76 percent. This is a 137.14 percent decrease over earnings of $0.35 per share

PBYI

6 minute read

Stocks That Hit 52-Week Lows On Thursday

By Benzinga Insights

Today, 2:25 PM

During Thursday's morning session, 77 companies made new 52-week lows.

AKRO

7 minute read

The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO

By Shanthi Rexaline

Today, 2:25 PM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4)

ABSI

34 minute read

Earnings Scheduled For August 5, 2021

By Benzinga Insights

Today, 2:25 PM

Companies Reporting Before The Bell • OneSpaWorld Holdings (NASDAQ:OSW) is projected to report quarterly loss at $0.20 per share on revenue of $6.42 million.

AAOI

5 minute read

Stocks That Hit 52-Week Lows On Wednesday

By Benzinga Insights

Today, 2:25 PM

Wednesday's morning session saw 58 companies set new 52-week lows.

AMYT

6 minute read

The Daily Biotech Pulse: Pfizer’s Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings

By Shanthi Rexaline

Today, 2:25 PM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 3)

ABSI

2 minute read

Puma Biotechnology Secures $125M Note Purchase By Athyrium Capital

By Bill Haddad

Today, 2:25 PM

Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that it has entered into a note purchase agreement with a fund of Athyrium Capital Management, LP, a specialized asset management company

PBYI

1 minute read

Puma Biotech’s Nerlynx Wins Canadian Approval In HER2-Positive Metastatic Breast Cancer

By Vandana Singh

Today, 2:25 PM

Health Canada has approved Puma Biotechnology Inc’s (NASDAQ:PBYI) Nerlynx (neratinib) in combination with capecitabine for metastatic HER2-overexpressed/amplified breast cancer, who…

KHTRF

2 minute read

Knight Therapeutics Announces Health Canada Approval For NERLYNX To Treat HER2-Positive Metastatic Breast Cancer

By Bill Haddad

Today, 2:25 PM

Knight Therapeutics Inc. (TSX:GUD), ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that Health Canada has approved NERLYNX® (neratinib) in combination with capecitabine

PBYI

2 minute read

Puma Biotechnology Announces FDA Approves Dose Escalation Label Update For Co.’s NERLYNX In HER2-Positive Early Stage and Metastatic Breast Cancer

By Bill Haddad

Today, 2:25 PM

Dose escalation of NERLYNX therapy demonstrated improved management and prevention of Grade 3 diarrhea Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that the U.S. Food and Drug

PBYI